We reported previously that the selective agonist U50,488H promoted phosphorylation of the mouse kappa opioid receptor (KOPR) at residues S356, T357, T363 and S369. Here, we found that agonist (U50,488H)-dependent KOPR phosphorylation at all the residues were mediated by Gi/o α proteins and multiple protein kinases [GRKs2, 3, 5 and 6 and protein kinase C (PKC)]. In addition, PKC activation by phorbol ester induced agonistindependent KOPR phosphorylation. Compared with U50,488H, PKC activation promoted much higher S356/T357 phosphorylation, much lower T363 phosphorylation and similar levels of S369 phosphorylation. Following U50,488H, GRKs, but not PKC, were involved in agonist-induced KOPR internalization. In contrast, PKC activation caused a lower level of agonist-independent KOPR internalization, compared to U50,488H. U50,488H-induced activation of extracellular signal regulated kinase 1/2 (ERK1/2) was G protein-, but not β-arrestin-, dependent. After U50,488H, GRKmediated, but not PKC-mediated, KOPR phosphorylation followed by β-arrestin recruitment desensitized U50,488H-induced ERK1/2 response. Therefore, agonistdependent (GRK-and PKC-mediated) and agonist-independent (PKC-promoted) KOPR phosphorylations show distinct phosphorylation patterns, leading to diverse cellular outcomes.
Introduction
The kappa opioid receptor (KOPR) is one of the three opioid receptors and belongs to the rhodopsin subfamily of G protein-coupled receptors (GPCRs). Activation of the KOPR produces many effects, including analgesia, antipruritic effects, water diuresis, hypothermia, sedation, and dysphoria (Ansonoff et al., 2006; Cowan et al., 2015; Lemos and Chavkin, 2011; Simonin et al., 1998) . At the cellular level, activation of KOPR stimulates Gi/o protein-mediated signaling and KOPR phosphorylation. Phosphorylated receptor recruits β-arrestin, leading to desensitization, internalization and β-arrestindependent signaling [reviewed in (Al Hasani and Bruchas, 2011; Law, 2011; Liu-Chen, 2004) ]. Gi/o protein-dependent responses include inhibition of adenylyl cyclases and Ca 2+ inward current, and activation of K + channels and ERK1/2 (early phase) (Al Hasani and Bruchas, 2011; Law, 2011) . β-arrestin-dependent signaling includes phosphorylation of ERK1/2 (late phase) and p38 MAP kinase (Al Hasani and Bruchas, 2011; Law, 2011) .
Previous studies using different strategies have shown that agonists cause KOPR phosphorylation. We have demonstrated that U50,488H induces phosphorylation of the human KOPR expressed in Chinese hamster ovary cells (CHO cells) using metabolic labeling with 32 P-orthophosphate (Li et al., 2002) . Chavkin and colleagues reported that U50,488H induced rat KOPR (rKOPR) phosphorylation at S369 in human embryonic kidney 293 cells (HEK293 cells) by immunoblotting (McLaughlin et al., 2003) . Recently, by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis, we determined the phosphorylation sites of the mouse KOPR (mKOPR) following U50,488H treatment to be S356, T357, T363 and S369 in the C-terminal domain (Chen et al., 2016) . Antibodies were generated against three phosphopeptides containing pS356/pT357, pT363 or pS369, respectively. Affinity-purified antibodies were extensively characterized and found to be highly specific in immunoblotting for the mouse KOPR phosphorylated at S356/T357, T363 or S369 (Chen et al., 2016) . U50,488H markedly enhanced staining intensity of the KOPR by immunoblotting with these three phospho-specific antibodies and the U50,488H effect was blocked by the selective KOPR antagonist norbinaltorphimine, indicating that U50,488H-induced KOPR phosphorylation at these sites is KOPR-mediated (Chen et al., 2016) .
5

Materials and methods
Materials
Mouse neuro2A neuroblastoma (N2A) cells were purchased from the A.T.C.C.
(Manassas, VA). U50,488H were provided by the National Institute on Drug Abuse (Bethesda, MD) . Horseradish peroxidase (HRP)-conjugated goat anti-rabbit or antimouse IgG antibodies were purchased from Jackson ImmunoResearch Laboratories (West Grove, PA). Minimal essential medium (MEM), blasticidin and Lipofectamine TM 2000 were purchased from Invitrogen/Thermo Fisher Scientific (Waltham, MA). Fetal bovine serum was purchased from Atlanta Biochemicals (Flowery Branch, GA). Protease inhibitor tablets and enhanced chemiluminescence (ECL) reagent Supersignal West Pico were purchased from Pierce/Thermo Fisher Scientific (Waltham, MA). Nickelnitrilotriacetate (Ni-NTA) agarose was purchased from Qiagen (Hilden, Germany).
Dodecyl-β-D-maltoside (DDM), Go6976 and PVDF membranes were purchased from EMD Millipore (Billerica, MA). Chelerythrine chloride (CHL) was from Enzo Life science (Farmingdale, NY) . [ 3 H]diprenorphine (specific activity 37 Ci/mmole) was purchased from PerkinElmer (Waltham, MA). Dynorphin A(1-17) was from Multiple Peptide System (SD, CA). Antibodies against total ERK1/2 (#4696) and phosphorylated ERK1/2 (#4370) were from Cell Signaling Technology (Danvers, MA). Secondary antibodies IRDye 800CW goat anti-rabbit IgG and IRDye680 goat anti-mouse IgG were from LI-COR Bioscience (Lincoln, NE). Takeda compound 101 (Compound 101; 2, methyl] amino]-N- [2-(trifuoromethyl) benzyl] benzamidehydrochloride) (Lowe et al., 2015) was from Hello Bio Inc. (Princeton, NJ 
Cell Culture
The mKOPR tagged with FLAG at the N-terminus and 6×His-tag at the Cterminus (FmK6H) was cloned into the vector pcDNA6. FmK6H was stably transfected into N2A cells and stable clonal N2A-FmK6H cells were selected (Chen et al., 2016) .
Cells were grown in 10% fetal bovine serum, 2.2 g L -1 NaHCO 3 , 110 mg L -1 pyruvic acid, 1 µg mL -1 blasticidin, MEM and 100 units mL -1 penicillin/streptomycin in a humidified atmosphere with 5% CO 2 , 95% air at 37°C.
Drug treatment
Effects of U50,488H on KOPR phosphorylation: time course and dose-response relationship
Cells at 80% confluency were incubated in serum-free medium for at least 1 hr.
For time-course experiments, cells were treated with vehicle or 0.1 µM U50,488H for different time intervals (0, 0.5, 1, 2, 5, 10 min) at 37°C. For concentration-response relationship, cells were treated with vehicle or different concentrations of U50,488H (0.01, 0.1, 0.3, 1, 3, 10 µM) for 2 min at 37°C.
Roles of GRKs in U50,488H-promoted KOPR phosphorylation
For knockdown of GRK isoforms, 5 x 10 5 cells/ well in 6-well plates were left untransfected or transfected with control siRNA (siCtrl) or siRNA targeting GRK2, GRK3, GRKs2+3 or GRK6 (75 pmole siRNA) using Lipofectamine 2000. Because GRK5 was not detected in N2A cells, effects of both overexpression and overexpression/ knockdown of GRK5 were examined. Cells were co-transfected with pcDNA3/ siCtrl, GRK5 cDNA/ siCtrl, pcDNA3/ GRK5 siRNA and GRK5 cDNA/ GRK5 siRNA (1 µg cDNA/100 pmole siRNA) using Lipofectamine 2000. Two days after transfection, cells were treated with vehicle or 3 µM U50,488H for 2 min at 37°C. Some cells were pretreated with compound 101 (3 and 30 µM) [concentrations based on (Lowe et al., 2015) ] for 30 min and then incubated with vehicle or 3 µM U50,488H for 2 min.
Effects of protein kinase C (PKC) activation on KOPR phosphorylation
Cells (~10 7 ) were incubated in serum-free medium for at least 1 hr, and then treated with different concentrations (0.001, 0.01, 0.1, 1 and 10 µM) of PMA, a PKC activator, for 30 min or treated with 0.1 µM PMA for different time points (0, 1, 5, 10 and 30 min) at 37°C. For comparison, 3 µM U50,488H was used for the same time intervals.
Effects of PKC inhibition on U50,488H-induced KOPR phosphorylation
Cells (~10 7 ) were incubated with serum-free medium for 1 hr followed by incubation with vehicle or a PKC inhibitor [4 µM GF109203X, 1 µM chelerythrine chloride (CHL) or 100 nM Go6976] [concentrations based on (Herbert et al., 1990; Jacobson et al., 1995; Martiny-Baron et al., 1993) ] for 30 min and then were treated with vehicle or 3 µM U50,488H for 2 min at 37°C. Some cells were transfected with control siRNA (siCtrl) or siRNA targeting PKCα or PKCε (75 pmole siRNA) using Lipofectamine 2000 and the 2 days later, cells were treated 3 µM U50,488H for 2 min.
Receptor purification and western blot
Receptor purification and subsequent immunoblotting were performed according to a simplified procedure of Chen et al. (Chen et al., 2016 (1 µg ml -1 , pS356/pT357, pT363 and pS369) overnight followed by HRP-conjugated goat anti-rabbit IgG antibodies and then reacted with ECL reagents. Images were captured with LAS 1000 plus Image Analyzer (Fuji Photo Film Co. Ltd., Tokyo, Japan).
Membranes were stripped and re-blotted for total mouse KOPR (anti-PA847, 10,000 -1 ).
Intensities of phospho-KOPR were normalized against that of the total KOPR in the same lane. Unless indicated otherwise, a U50,488H response (usually the maximal response) was designated as 100% and others were normalized against it.
Reverse transcription-polymerase chain reaction (RT-PCR)
Cells (~10 7 ) were solubilized with 1 ml Trizol reagent followed by RNA extraction and precipitation for RT-PCR. 
KOPR internalization
Some cells were treated with 0.1 µM PMA for 30 min. Some other cells were incubated with a PKC inhibitor (4 µM GF109203X or 1 µM CHL) for 30 min followed by 3 µM U50,488H for 30 min. Cells were quickly suspended in PBS containing 1mM EDTA and then washed three times for 10 min with 0.1% BSA in PBS at 4°C to remove PMA or U50,488H. KOPR internalization was determined by radioligand binding to KOPR in intact cells as described previously (Li et al., 1999) . Receptor binding was carried out using 1 nM [ 3 H]diprenorphine. Specific binding to total receptors was defined in the presence of naloxone (10 µM), whereas specific binding to cell surface receptors was determined in the presence of dynorphin A-(1-17) (1 µM). Thus, the intracellular receptor pool can be calculated by subtracting cell surface receptor binding from total receptor binding. The internalized receptors were calculated as (intracellular receptor pool of U50,488H-treated groupintracellular receptor pool of control group) / intracellular receptor pool of control group.
ERK1/2 activation by U50,488H
For time course study, cells were treated with 3 µM U50,488H at 37°C for different durations (0, 1, 2, 5, 10, 20, 30 min and 1, 2, 3, 4 hr). For involvement of G proteins, cells were treated with or without PTX (200 ng ml -1 , 2 hr, 37ºC) and subsequently with 3 µM U50,488H or vehicle for 5 min or 1 hr. For the roles of GRKs and β-arrestins, cells were transfected with siRNA control or siRNA against GRK2+3, GRK6, β-arrestin1 or β-arrestin2 for 2 days as described above and then treated with 3 µM U50,488H for 5 min or 1 hr at 37°C.
All treated cells were lysed with 2x Laemmli sample buffer (4% SDS, 100 mM DTT, 10% glycerol, 62.5 mM Tris, 0.01% bromophenol blue, pH6.8). Cell lysate was subject to 8% SDS-PAGE and resolved protein bands were then transferred onto nitrocellulose membranes. Membranes were incubated with primary antibodies against β-arrestin1 (1:5000), β-arrestin2 (1:6000), GRK2 (1:1000), GRK3 (1:1000), GRK4/5/6
(1:2000) or pERK1/2 (1:3000) and total ERK1/2 (1:3000) overnight at 4°C followed by goat anti-mouse IgG conjugated with infrared dye 680 or goat anti-rabbit IgG conjugated with infrared dye 800CW (1:10,000). Images were captured with the Odyssey Infrared
Imaging System (LI-COR Biosciences, Lincoln, NE).
Data Analysis and Statistics
Data were graphed and analyzed with Graph Pad Prism5.01 (La Jolla, CA). Oneway ANOVA was used to analyze one-factor experiment, followed by Newman-Keuls post-hoc test. Two-way ANOVA was used to analyze two-factor experiments followed by Bonferroni or Newman-Keuls post-hoc test.
Results
Time course of U50,488H-induced KOPR phosphorylation
N2A-FmK6H cells were treated with 0.1 µM U50,488H for 0.5, 1, 2, 5 and 10 min.
U50,488H very rapidly induced KOPR phosphorylation at S356/T357, T363 and S369, reaching a plateau in 30 sec, 1 min and 2 min, respectively ( Fig. 1A) . Thus, for the subsequent experiments, 2-min incubation time with U50,488H was chosen. In addition, S356/T357 showed basal phosphorylation without U50,488H treatment, similar to our previous finding (Chen et al., 2016) .
Dose-response relationship of U50,488H-induced KOPR phosphorylation
Cells were treated with 0.01, 0.1, 0.3, 1, 3 and 10 µM U50,488H for 2 min.
U50,488H promoted KOPR phosphorylation in a dose-dependent manner at each residue ( Fig. 1B) . The pEC 50 values (95% confidence limits, CI) for phosphorylation at S356/T357, T363 and S369 were determined to be 6.40 (95% CI, 6.07-6.76), 6.32 (95% CI, 5.69-6.95) and 6.63 (95% CI, 6.46-6.79), respectively. The means of EC 50 values for S356/T357, T363 and S369 phosphorylation were 0.39 µM, 0.48 µM and 0.24 µM, respectively. There was no significant difference among the three EC 50 values (one-way ANOVA followed by Newman-Keuls post-hoc test, p=0.99). Based on these results, 3 µM U50,488H was chosen for the following experiments.
Roles of Gi/o proteins in U50,488H-indcued KOPR phosphorylation
Cells were pretreated with pertussis toxin (PTX) followed by U50,488H
incubation. PTX significantly reduced U50,488H-induced KOPR phosphorylation at S356/T357, T363 and S369 by 81 ± 8%, 52 ± 6% and 62 ± 5%, respectively (Fig. 2) . The reduction in S356/T357 phosphorylation was significantly higher than T363 phosphorylation (one-way ANOVA followed by Newman-Keuls post-hoc test, p<0.05).
The results indicate activation of G i/o proteins is involved in KOPR phosphorylation at each phosphosite and pS356/T357 was more highly regulated by Gi/o proteins than other residues.
Roles of GRKs in U50,488H-induced KOPR phosphorylation
GRKs are major protein kinases involved in agonist-induced GPCR phosphorylation. We found that N2A cells endogenously express GRK2, GRK3 and GRK6, but not GRK5, by western blot with GRK2, GRK3 and pan GRKs4/5/6 antibodies (see Fig. 3 ).
Knockdown of GRK2 or GRK3 decreased U50,488H-promoted phosphorylation at S356/T357 by 77 ± 12% and 76 ± 16%, respectively, whereas knockdown of both totally blocked phosphorylation (115 ± 11%). All the values are mean ± SEM (n=3-6).
For T363, knockdown of GRK2 reduced phosphorylation by 63 ± 9%, while knockdown of GRK3 and GRKs2/3 reduced by 80 ± 5% and 79 ± 8 %, respectively. For S369, knockdown of GRK2 inhibited phosphorylation by 38 ± 3%, whereas knockdown of GRK3 and GRKs2/3 reduced by 62 ± 4% and 68 ± 4%, , respectively (Fig. 3A) . The control siRNA did not affect U50,488H-promoted phosphorylation at S356/T357, T363
and S369, compared to no transfection (NTF). Therefore, NTF was omitted in the subsequent experiments involving siRNA. Knockdown of GRK6 reduced U50,488Hcaused KOPR phosphorylation at S356/T357, T363 and S369 by 60 ± 11%, 47 ± 5% and 53 ± 5%, respectively (Fig. 3B) . These results indicate that GRK2, GRK3 and GRK6 are involved in KOPR phosphorylation at all four residues upon U50,488H stimulation.
GRK2 alone or GRK2+3 shows higher involvement at S356/T357 than T363 and S369 ( Fig. 7 ).
GRK5 was reported to participate in agonist-induced KOPR desensitization (Appleyard et al., 1999) , suggesting that GRK5 is involved in KOPR phosphorylation.
Since N2A cells do not express GRK5 endogenously, we examined the role of GRK5 by its expression and expression + knockdown. Expression of GRK5 promoted higher levels of KOPR phosphorylation at S356/T357, T363 and S369 by 2-, 1.6-and 1.6-fold, respectively, compared with the vector control. Co-transfection of GRK5 and GRK5 siRNA blocked GRK5 expression-caused KOPR phosphorylation at S356/T357, T363
and S369 by 64 ± 9%, 42 ± 8% and 38 ± 3 % ( Fig. 3C ). GRK5 is more involved in phosphorylating S356/T357 than the other two residues (Fig. 7) .
Knockdown efficiency for each GRK was determined ( Fig. 3 left panel) . GRK2 siRNA or GRK2 + 3 siRNAs reduced GRK2 by 47 ± 6% and 48 ± 4%, respectively, compared to control siRNA. Similarly, GRK3 siRNA or GRK2 + 3 siRNAs reduced GRK3 by 48 ± 8% and 47 ± 7%, respectively. GRK6 siRNA reduced GRK6 levels by 40 ± 5%. GRK5 siRNA reduced the overexpression level of GRK5 by 79 ± 3%. The specificity of each individual siRNA against GRKs 2, 3, 5 and 6 for its target vs. other
GRKs was confirmed (data not shown).
We also used the GRK2/3 inhibitor compound 101 (Lowe et al., 2015) S1 ). The results are similar to those obtained with siRNA. Compound 101 at 3 µM showed similar levels of reduction as knockdown of GRK2+3. GRK2+3 and compound 101 regulated S356/T357 more than T363 and S369 ( Fig. 7) . Compound 101 at 30 µM reduced basal S356/T357 phosphorylation.
Taken together, U50,488H-induced KOPR phosphorylation at S356/T357, T363 and S369 was regulated by GRK2, GRK3, GRK5 and GRK6. All four phosphoresidues are regulated concertedly by the four GRKs. GRK2, GRK2+3 and GRK5 appear to more involved in phosphorylating S356/T357 than T363 and S369 (S356/T357> T363= S369) ( Fig. 7 ). GRK3 and GRK6 are similarly involved in phosphorylating the four residues (S356/T357= T363= S369) ( Fig. 7 ).
Roles of PKCs in KOPR phosphorylation
PKC was reported to be involved in homologous and heterologous phosphorylation of GPCRs, including MOPR and free fatty acid receptor4 (Burns et al., 2014; Mann et al., 2015) . Activation of the KOPR by agonists has been shown to stimulate PKC (Bian et al., 2000; Bohn et al., 2000) . S356, T357, T363 and S369 are also PKC consensus phosphorylation sites. Thus, whether PKC regulates agonist-independent and agonist-dependent KOPR phosphorylation was characterized.
Using RT-PCR, we have found that N2A cells endogenously express eight PKC isoforms: PKCα, PKCβ and PKCγ (conventional PKCs), PKCζ and PKCι/λ (atypical PKCs), as well as PKCδ, PKCε and a low level of PKCθ, but not PKCη (novel PKCs) ( Fig 4) .
Roles of PKCs in agonist-dependent KOPR phosphorylation
Knockdown of PKCα or PKCε by isoform-specific siRNA, which reduced each isoform level by 45% and 43%, respectively, did not significantly affect U50,488Hinduced KOPR phosphorylation at any of the four sites (Supplemental Fig. S2 ). It is likely that siRNA knockdown of one isoform may lead to substitution by other PKC isoforms. Thus, PKC inhibitors were used subsequently to examine agonist-dependent KOPR phosphorylation.
The non-selective PKC inhibitor GF109203X (4 µM) reduced U50,488H
promoted KOPR phosphorylation at S356/T357, T363 and S369 by about 100 ± 1%, 59 ± 10% and 27 ± 12%, respectively (Fig. 5A ). The extents of reduction by GF109203X were significantly different among the residues (Fig. 7) . In addition, GF109203X lowered the basal phosphorylation level of S356/T357, but not T363 and S369 (Fig. 5A ). Another non-selective PKC inhibitor chelerythrine (CHL) (1 µM) significantly decreased U50,488H-promoted KOPR phosphorylation at T363 and S369 by 58 ± 10% and 61 ± 5%, respectively, but had no effect at S356/T357 (16 ± 12%), without affecting basal phosphorylation (Fig. 5B ). The selective PKCα and PKCβ1 inhibitor Go6976 (100 nM) reduced U50,488H-induced KOPR phosphorylation at S356/T357 and S369 by 36 ± 18% and 22 ± 12%, respectively, but not at T363 (-7 ± 11%), with no effect on basal phosphorylation (Fig. 5C) . These results indicate different PKC isoforms contribute to U50,488H-induced KOPR phosphorylation in site-specific manner. In addition, PKC is involved in basal KOPR phosphorylation at S356/T357.
Activation of PKCs increased agonist-independent KOPR phosphorylation
Whether PKC activation promoted agonist-independent KOPR phosphorylation was studied using the PKC activator PMA. U50,488H-induced KOPR phosphorylation at S356/T357 in Fig. 6B showed lower signals than in Fig. 1A . Since PMA-induced KOPR phosphorylation at S356/T357 yielded very high signals (Fig. 6B) , the U50,488H-induced pS356/T357 signals in Fig.   6B were captured with shorter exposure time to prevent the PMA signals from being over-exposed. In addition, PMA-induced KOPR phosphorylation at pT363 in Fig. 6B showed weaker signal than that in Fig. 6A (see the signals at 0.1 µM, 30 min) because they were captured with shorter exposure time to prevent the U50,488H signals in Fig.   6B from overexposure.
Phosphorylation patterns: regulation of U50,488H-induced site-specific phosphorylation by distinct protein kinases Figure 7 summarizes the involvement various kinases in U50,488H-promoted phosphorylation of the four residues in the KOPR. Different residues were regulated to different degrees by multiple protein kinases. For GRKs, although the four GRK isoforms regulated all the phosphoresidues on KOPR, each had different degrees of involvement in phosphorylating the four sites. GRK2, GRK2+3 and GRK5 phosphorylated S356/T357 more than T363 and S369 (S356/T357> T363= S369). GRK3 and GRK6 phosphorylated all the residues to similar extents (S356/T357= T363= S369). For PKC, GF109203X suppressed U50,488H-induced phosphorylation in the degrees of S356/T357>> pT363> pS369. CHL inhibited phosphorylation of T363 and S369 similarly, but had no effect on phosphorylation of S356/T357. Go6976 suppressed KOPR phosphorylation at S356/T357 and S369 (S356/T357= S369), but not at T363. Whether differences in protein kinasemediated KOPR phosphorylation lead to diverse functional outputs was examined below.
Effects of protein kinase-mediated KOPR phosphorylation on cellular functions
GPCR phosphorylation is the initial step in desensitizing G protein-mediated signaling as well as in initiating β-arrestin-dependent signaling and receptor internalization. Thus, we examined the effect of protein kinase-mediated KOPR phosphorylation on receptor internalization (Fig. 8 ) and the downstream signaling ( Fig.   9 ).
Effects of agonist-dependent and -independent KOPR phosphorylation on KOPR internalization
Knockdown of GRKs2/3 or GRK6 decreased U50,488H-induced KOPR internalization from ~60% to ~ 30% and ~40%, respectively (Fig. 8A) , indicating that GRKs2/3 and GRK6 are involved in U50,488H-induced KOPR internalization. Inhibition of PKC by GF109203X or CHL did not affect U50,488H-induced internalization (Fig.   8B ). Therefore, GRK-mediated, but not PKC-mediated, KOPR phosphorylation, causes U50,488H-induced internalization. In addition, PMA induced ~12% KOPR internalization, much lower than U50,488H (Fig. 8B) .
Comparison between Fig. 8A and Fig. 8B showed that U50,488 induced internalization of 60% and 43% of cell surface KOPR, respectively. The different extents of internalization are likely due to influence of transfection on cells. Results presented in internalization. This is a limitation of using the transfection procedures.
Roles of protein kinase-mediated KOPR phosphorylation in U50,488H-induced ERK1/2 signaling
KOPR activation has been shown to activate ERK1/2 (Belcheva et al., 1998; Bruchas et al., 2006) . Incubation of cells with U50,488H for different durations (1, 2, 5, 10, 20, 30 min and 1, 2, 3, 4 hr) increased pERK1/2 levels with a peak at 5 min (defined as 100%), followed by a decline to about 40-50% and then sustained stimulation at 40-50% for up to 4 hr (Fig. 9A ).
The roles of Gi/o proteins, GRKs and β-arrestins in U50,488H-induced ERK1/2 activation at 5 min and 1 hr were examined. PTX pretreatment blocked U50,488Hinduced ERK1/2 phosphorylation at 5 min and 1 hr (Fig. 9B) , indicating that both are G protein-dependent. Thus, in this N2A cell system, there is no differentiation between early phase and late phase of ERK1/2 activation as shown by McLennan et al.(McLennan et al., 2008) . Knockdown of GRK2/GRK3 or GRK6 enhanced ERK1/2 activation at 5 min and 1 hr (Fig. 9C ). Agonist-caused GPCR phosphorylation leads to β-arrestin recruitment, so the role of β-arrestins in U50,488H-induced ERK1/2 activation was examined. Knockdown of β-arrestin 1 or β-arrestin 2, which reduced β-arrestin 1 or βarrestin 2 by 38 ± 5% or 45 ± 6%, respectively, increased ERK1/2 activation at 5 min and 1 hr (Fig. 9D ), similar to the GRK knockdown results. These results indicate that U50,488H-induced ERK1/2 phosphorylation is G protein-, but not GRK-or β-arrestin-, dependent. Instead, GRK-mediated KOPR phosphorylation followed by β-arrestin recruitment is involved in desensitization of G protein-mediated ERK1/2 signaling.
We also examined if U50,488H-induced PKC-mediated KOPR phosphorylation regulated desensitization of G protein-mediated ERK1/2 activation. Treatment of cells with CHL (1 µM) did not affect U50,488H-induced ERK1/2 activation at 5 min and 1 hr ( Fig. 9E) , demonstrating that PKC is not involved. Thus, GRK-mediated, but not PKCmediated, KOPR phosphorylation plays a role in desensitization of G protein-mediated ERK1/2 signaling.
Discussion
Our studies have shown that Gi/o α proteins and multiple protein kinases (GRKs2, 3, 5, 6 and PKC) are involved in agonist (U50,488H)-induced KOPR phosphorylation and PKC also promotes agonist-independent KOPR phosphorylation. GRK-, but not PKC-, mediated agonist-dependent KOPR phosphorylation is involved in KOPR internalization and desensitization of G protein-dependent ERK1/2 phosphorylation.
PMA-induced agonist-independent KOPR phosphorylation results in lower extent of receptor internalization than U50,488H. KOPR is phosphorylated by U50,488H (GRKand PKC-mediated) and PMA (PKC activation) in distinct phosphorylation patterns, leading to differential KOPR functional regulations (internalization and desensitization).
To the best of our knowledge, this is the first demonstration that PKC and GRK6 are involved in KOPR phosphorylation and that different KOPR phosphorylation patterns cause distinct functional consequences.
Multiple protein kinases-induced KOPR phosphorylation and the barcode hypothesis
The "barcode" hypothesis postulates that different kinases phosphorylate distinct residues of GPCRs, leading to distinct functional outcomes (Butcher et al., 2012; Nobles et al., 2011) . For example, upon agonist treatment, the M3 muscarinic receptor phosphorylation is involved in desensitization of the phospholipase C pathway and receptor internalization, whereas casein kinase 1α -and casein kinase 2-mediated phosphorylation impacts on ERK1/2 and JUN kinase pathways, respectively [reviewed in (Butcher et al., 2012) ]. In this study, following U50,488H treatment, GRK-mediated, but not PKC-mediated, phosphorylation is involved in U50,488H-induced internalization and desensitization of ERK1/2 signaling. PKC-activated agonist-independent KOPR phosphorylation caused lower degrees of internalization, compared to U50,488H. Thus, it is likely that fine tuning on phosphorylation of the four KOPR residues by multiple protein kinases (GRKs and PKC isoforms) via different phosphorylation patterns (residues and levels) provides a regulatory mechanism contributing to diverse cellular outcomes.
Interestingly, all four GRK isoforms (GRKs 2, 3, 5 and 6) are involved in KOPR phosphorylation at all the four residues. GRK2, GRK2+3 and GRK5 show more involvement in phosphorylating S356/T357 than T363 and S369, whereas GRK3 and GRK6 phosphorylated all the residues to similar degrees. It is noteworthy that siRNA knockdown of any of GRKs 2, 3 or 6 alone greatly decreased U50,488H-promoted KOPR phosphorylation, suggesting that concerted activities of all three endogenous GRKs are required to fully phosphorylate KOPR. Similarly, knockdown of GRKs 2/3 or GRK6 profoundly increased U50,488H-induced ERK1/2 phosphorylation and largely attenuated U50,488H-caused internalization, demonstrating that combined effects of GRKs2/3 and GRK6 are needed for full desensitization and internalization of the receptor.
GRKs have been reported to be regulated by PKC. PKC phosphorylates GRK2 and GRK5, leading to GRK2 activation, but GRK5 inhibition (Chuang et al., 1995; Pronin and Benovic, 1997; Winstel et al., 1996) . N2A cells endogenously express GRK2, but not GRK5. The possibility cannot be excluded that effects of PKC inhibition are in part due to GRK2 inhibition, resulting in reduced KOPR phosphorylation. On the other hand, since compared with U50,488H, PMA induced much higher S356/T357 phosphorylation and much lower T363 phosphorylation and PMA promoted much slower S369 phosphorylation, it is unlikely that the actions of PMA were through GRK2 activation.
Different cells or tissues are likely to express different populations and levels of GRKs, PKC isoforms and other protein kinases, leading to distinct phosphorylation patterns and functional consequences. For example, U50,488H did not cause internalization of rKOPR in CHO cells (Li et al., 1999) , but did so in HEK293 cells (McLaughlin et al., 2003) . Therefore, GPCR phosphorylation show cell-specific and tissue-specific, leadind to recruitment of different levels of β-arrestins, activation of different downstream signal pathways and ultimately unique physiological and pharmacological responses (Tobin, 2008; Tobin et al., 2008) .
The role of PKC in basal and U50,488H-induced KOPR phosphorylation
U50,488H-induced KOPR phosphorylation was inhibited to different degrees by GF109203X at all the four residues (Fig. 5A) , by CHL at two residues (T363 and S369) ( Fig. 5B) , and by Go6976 at three residues (S356/T357 and S369) ( Fig. 5C ). GF109203X inhibits all PKC isoforms (conventional, novel and atypical PKCs) (Hofmann, 1997; Martiny-Baron et al., 1993) , while CHL affects two PKC subfamilies (conventional and novel PKCs) (Herbert et al., 1990) . Go6976 is a selective PKCα and PKCβ1 inhibitor.
Thus, the three inhibitors reduced KOPR phosphorylation at the same residues to different degrees, which is likely due to their diverse effects on PKC isoforms and different extents of inhibition on each isoform. In addition, the findings that GF109203X, but not CHL and Go6976, reduced basal KOPR phosphorylation at S356/T357 indicate that atypical PKC isoforms play roles in basal S356/T357 phosphorylation. PKC has been reported to be involved in basal phosphorylation at S363 of MOPR and morphinedependent MOPR phosphorylation (Chen et al., 2013; Hull et al., 2010; Johnson et al., 2006) .
PKC mediated agonist-independent KOPR phosphorylation
PMA, which activates conventional and novel PKCs, promoted KOPR phosphorylation at S356/T357, T363 and S369 (Fig. 6) . PKC-mediated agonistindependent KOPR phosphorylation may be involved in heterologous desensitization of KOPR. PKC was reported to promote agonist-independent phosphorylation of other GPCRs, such as MOPR (Illing et al., 2014) and FFA4 receptor (Burns et al., 2014) .
Role of Gi/o proteins in U50,488H-induced KOPR phosphorylation
Pretreatment with PTX decreased U50,488H-stimulated KOPR phosphorylation at S356/T357, T363 and S369 (Fig. 2) , indicating involvement of Gi/o proteins. The role of Gi/o proteins is likely related to their regulation of GRKs and PKC. Following G protein activation by GPCRs, GRKs 2 and 3 are recruited to plasma membranes by association with G βγ proteins. PTX inhibits Gi/o α proteins activation and thus blocks release of G βγ subunits, resulting in no activation of GRKs 2 and 3. In addition, PKC activation is downstream of KOPR and G protein activation (Belcheva et al., 2005; Bohn et al., 2000) . Thus, inactivation of Gi/o proteins may also impair PKC-mediated KOPR phosphorylation following U50,488H treatment.
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Effects of agonist-dependent and -independent KOPR phosphorylation on receptor internalization
Our results that GRKs2/3 and GRK6, but not PKC, are involved in U50,488Hinduced KOPR internalization (Fig. 7) are consistent with previous reports. GRK2 and GRK3 are involved in U50,488H-induced internalization of the human and the rat KOPR (Li et al., 1999; McLaughlin et al., 2003; Schulz et al., 2002) . The PKA/PKC inhibitor staurosporine did not inhibit U50,488H-induced rat KOPR internalization (McLaughlin et al., 2003) .
We previously showed that U50,488H caused higher phosphorylation level at S356/T357, T363 and S369 and produced more double and triple phosphorylation, compared to etorphine. U50,488H induced KOPR internalization, but etorphine did not, indicating above-threshold KOPR phosphorylation is required for KOPR internalization (Chen et al., 2016) . Knockdown of GRK2+3 and GRK6 affected all KOPR phosphoresidues more than PKC inhibitors (Fig.7) . Thus, U50,488H-promoted PKCmediated KOPR phosphorylation may be below the threshold necessary for internalization. PMA induced a low level of KOPR internalization, indicating PMApromoted an above-threshold KOPR phosphorylation to trigger internalization.
Compared to U50,488H, PMA promoted much higher S356/T357 phosphorylation, much lower T363 phosphorylation and a similar level of S369
phosphorylation. In addition, PMA-promoted KOPR phosphorylation at S369 reached plateaus at later time than U50,488H (Fig. 5 ). Another possibility for lower internalization by PMA is phosphorylation rates. Thus, spatial and temporal regulations on KOPR phosphorylation may contribute to different cellular outcomes.
In summary, agonist-dependent (GRK-and PKC-mediated) and agonistindependent (PKC activation) KOPR phosphorylation yield different levels and rates of phosphorylation at each residue, leading to different internalization outputs.
Role of receptor phosphorylation in KOPR signaling
Knockdown of GRKs increased U50,488H-induced ERK1/2 activation, suggesting that GRK-mediated KOPR phosphorylation desensitizes agonist-induced G protein-dependent ERK1/2 signaling. These results are similar to those of Doll et al (Doll 21 et al., 2012) on the MOPR. In contrast, PKC-mediated KOPR phosphorylation is not involved in this desensitization. Taken together, GRK-mediated and PKC-mediated KOPR phosphorylation showed distinct regulations for desensitization of G proteindependent signaling. One possible explanation is that GRK-, but not PKC-, mediated KOPR phosphorylation reaches a level to cause desensitization.
Our findings that GRKs and β-arrestins desensitized U50,488H-induced Gi/omediated ERK1/2 activation are consistent with those of Chavkin and colleagues that U69,593-induced rKOPR desensitization was regulated by GRK3, GRK5 and β-arrestin 2 (Appleyard et al., 1999) .
Our result that PKC was not involved in U50,488H-induced ERK1/2 activation in N2A cells is different from the observations of Coscia and colleagues in C6 glioma and astrocytes (Belcheva et al., 2005; Bohn et al., 2000) . The differences are likely due to cell systems used.
Our observation that U50,488H-induced ERK1/2 phosphorylation was G proteindependent without β-arrestin involvement in N2A cells is similar to those of Jamshidi et al. (Jamshidi et al., 2015) in peripheral sensory neurons. In contrast, in astrocytes, 
Figure 2. Effects of PTX on U50,488H-induced KOPR phosphorylation
Cells were pretreated with 200 ng/ml PTX for 2 hr followed by a 2-min incubation with 3 µM U50,488H. Experiments were performed as described in Fig. 1 legend. The data shown are the mean ± S.E.M (n=3) and were analyzed by two-way ANOVA followed by Newman-Keuls post-hoc test (***: p <0.001, compared to control group; ### : p <0.001, compared to U50,488H-treated group). (si6). Two days later, cells were treated with vehicle or 3 µM U50,488H for 2 min. Data were normalized against that of U50,488H-treated siRNA control group (siC-U50) and
shown as the mean ± S.E.M (n=3-6). Knockdown of GRK2, GRK3 and GRK6 was verified by western blot with specific antibodies.
(C) Effects of GRK5 expression and expression + knockdown on U50,488H-induced
KOPR phosphorylation Cells were co-transfected with the vector pcDNA3 and control siRNA (C), GRK5 cDNA and control siRNA (5), and GRK5 cDNA and GRK5 siRNA 
